RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY STUDY OF GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR GENE TRANSFER (AAV2-GDNF) IN MULTIPLE SYSTEM ATROPHY
Eligibility
You can join if...
Inclusion Criteria:
Male and female adults 35-75 years of age (inclusive)
Diagnosed with MSA with sporadic, adult-onset (>30 yo) with predominant parkinsonian symptoms
Less than 4 years from clinical diagnosis of MSA with expected survival > 3 years
Stable medication regimen
Ability to walk with or without an assistive device
Exclusion Criteria:
Presence of idiopathic Parkinson's disease or other neurological diseases
Myocardial sympathetic denervation inconsistent with an MSA diagnosis
Presence of dementia, psychosis, substance abuse or poorly controlled depression
Prior brain surgery (i.e. deep brain stimulator) or other brain imaging abnormalities
Receiving an investigational drug
History of cancer or poorly controlled medical conditions that would increase surgical risk
Inability to tolerate laying flat in an MRI or allergy to gadolinium
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.